MARKET

VERV

Verve Therapeutics, Inc.
VERV
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-4.7455
30.55
2.087
992,164,227.81
Eli Lilly Reports Q2 2025 Revenue Surge of 38% to $15.56 Billion, EPS Up 92% to $6.29
Reuters · 08/07 10:46
Weekly Report: what happened at VERV last week (0721-0725)?
Weekly Report · 07/28 09:28
*News On Verve Therapeutics Inc. (VERV) Now Under LLY
Dow Jones · 07/25 21:08
Verve Therapeutics Announces Merger and Nasdaq Delisting
TipRanks · 07/25 20:51
Verve Therapeutics Inc. Announces Delisting from Nasdaq Following Merger Completion
Reuters · 07/25 20:17
Eli Lilly completes acquisition of Verve Therapeutics
TipRanks · 07/25 12:56
*Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV
Dow Jones · 07/25 12:49
Eli Lilly And Verve Therapeutics Announces That The Tender Offer For All Outstanding Verve Shares, Priced At $10.50 Per Share In Cash Plus A Potential Additional $3.00 Via A Non-Tradable Contingent Value Right, Officially Expired At 12:01 A.M. Et On July 24, 2025. The Offer Was Not Extended.
Benzinga · 07/24 12:05
More

Webull offers Verve Therapeutics, Inc. stock information, including NASDAQ: VERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERV stock methods without spending real money on the virtual paper trading platform.